Biogen's dapirolizumab pegol shows higher lupus response rates than placebo in post-hoc trial analysis
BIIB•Biogen and UCB reported higher treatment responses with investigational dapirolizumab pegol than with placebo, alongside standard care, in post-hoc Phase 3 analyses of systemic lupus erythematosus. Results are being presented at ACR Convergence 2026, and the novel response measure requires further validation.
1. Post-hoc findings
Post-hoc Phase 3 analyses showed more sustained low disease activity and remission with dapirolizumab pegol than with placebo, each alongside standard care. Adverse events were more common with the drug, but serious events were less frequent; discontinuations remained low in both groups. The novel treatment-response measure was not a prespecified trial endpoint and requires further validation.
2. Conference presentation
The results are being presented at ACR Convergence 2026 in Orlando, Florida, November 6-11.
